Business
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established
About this update from Fulgent Genetics, Inc.
[{"type":"text","content":" EL MONTE, Calif.--(BUSINESS WIRE)--\nFulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that Phase 1/1b clinical data on its lead therapeutic development candidate, FID-007, to treat various solid tumors, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at 8:00 a.m. Central Time on June 3, 2023 in Chicago, Illinois.\n\n\nDetails of the presentation are as follows:\n\n\nAbstract Title: A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors\nSession: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology\nPresenters: Drs. Jacob Thomas and Anthony El-Khoueiry of University of Southern California\nPresentation Date and Time: June 3, 2023, at 8:00 a.m. Central Time\nPresentation Type: Poster Session\nAbstract #3026, poster board #224\n\n\nAbout FID-007\n\n\nFID-007 consists of paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer excipient designed to enhance PK, biodistribution, and tolerability. In addition to allowing the drug to remain in solution until it can enter a cancer cell, the PEOX nanoparticle is designed to preferentially deliver paclitaxel to the tumor through the leaky hyperpermeable vasculature.\n\n\nAbout Fulgent Pharma\n\n\nFulgent Pharma has developed and possesses a novel nanoencapsulation technology, which includes over 40 patents and a targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of both new and existing cancer drugs. Fulgent Pharma began as Fulgent Therapeutics in Temple City, California, in June 2011. As the company progressed into the sphere of personalized medicine, it also started delving into clinical genetic testing – a natural complement. In 2016, Fulgent Therapeutics split into two separate entities – Fulgent Pharma and Fulgent Genetics – in order to better pursue their independent objectives. Today, Fulgent Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers. Its partners in this endeavor include the University of Southern California, Moffitt Cancer Center, and ANP Technologies.\n\n\nAbout Fulgent\n\n\nFulgent is a technolog...